Russ Conroy

KEYNOTE-B96 showed pembrolizumab-based therapy improved PFS and OS in PD-L1–positive platinum-resistant ovarian cancer.

The phase 2b SURVIVE trial of SurVaxM in newly diagnosed glioblastoma will continue as planned following an interim review by an independent safety board.

Black and Hispanic pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or consolidation trials.

Early-phase LUPER trial results suggest the lurbinectedin/pembrolizumab combination may benefit patients with relapsed small cell lung cancer.

Final data from the phase 3 ALCYONE trial support frontline use of daratumumab-based therapy for patients with transplant-ineligible newly diagnosed multiple myeloma.

Using tools like the ICE Score could improve consistency in grading neurotoxicity tied to bispecific antibodies in hematologic cancers.

The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in camrelizumab/rivoceranib for advanced HCC.

Updated MAIA trial results reinforce the frontline benefit of daratumumab plus lenalidomide/dexamethasone in transplant-ineligible NDMM.

A phase 2 trial found that pembrolizumab plus pemetrexed met its objective response rate primary end point.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with HER2-positive gastric cancers enrolled in the INNOVATION trial.

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a CLEER-001 trial.

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to confirm this finding.

“This benefit in local recurrence translates into a later difference in distant recurrence and breast cancer [mortality], but it’s only apparent with long follow-up,” according to the study author.

Mirdametinib led to confirmed responses and meaningful pain and health-related quality of life improvements in both children and adults with neurofibromatosis type 1-associated PNs.

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Mitazalimab combined with mFOLFIRINOX led to responses and survival benefits in patients with metastatic pancreatic ductal adenocarcinoma.

Surveyed individuals who identified as a racial or ethnic minority reported difficulties discussing cancer diagnosis and treatment.

Brexu-cel is effective in treating patients with relapsed/refractory B-cell acute lymphoblastic leukemia, real-world data shows.

Patients with extensive-stage small cell lung cancer tended to have better PFS and OS with complete consolidative radiotherapy compared to incomplete consolidative radiotherapy.

Nivolumab plus AVD outperformed brentuximab vedotin plus AVD in patients with advanced-stage classical Hodgkin lymphoma.

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.

Adding talazoparib to enzalutamide improved survival in patients with metastatic castration-resistant prostate cancer.

A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.

The addition of nivolumab to radiotherapy significantly improved freedom from biochemical recurrence in patients with high-grade prostate cancer.

ODAC voted against the use of PD-L1 expression as a predictive biomarker in gastric cancers.

Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Consolidation durvalumab improved survival across subgroups of patients with limited-stage small cell lung cancer based on factors associated with prior prophylactic cranial irradiation and concurrent chemoradiotherapy use.